DOI: 10.4244/EIJV9I8A170

The coronary artery bypass graft SYNTAX Score: final five-year outcomes from the SYNTAX-LE MANS left main angiographic substudy

Vasim Farooq1, MBChB, MRCP; Chrysafios Girasis1, MD; Michael Magro1, MD; Yoshinobu Onuma1, MD; Marie-Angèle Morel2, BSc; Jung Ho Heo1, MD; Hector M. Garcia-Garcia2 , MD; Arie Pieter Kappetein3, MD, PhD; Marcel van den Brand2, MD; David R. Holmes4, MD; Michael Mack5, MD; Ted Feldman6, MD; Antonio Colombo7, MD; Elisabeth Ståhle8, MD; Stefan James8, MD; Didier Carrié9, MD; Gerard Fournial9, MD; Gerrit Anne van Es2, PhD; Keith D. Dawkins

We recently reported the coronary artery bypass graft (CABG) SYNTAX Score, an objective measure of anatomical complexity and revascularisation post coronary artery bypass graft (CABG) surgery1. At four-year follow-up, a non-significant trend towards more adverse clinical outcomes, including all-cause death, was reported in the higher CABG SYNTAX group (≥22)1. The final five-year outcomes of the SYNTAX trial have recently been reported2,3. We report the five-year outcomes of the CABG SYNTAX Score from the CABG arm of the SYNTAX-LE MANS left main angiographic substudy.

At five years, significantly greater all-cause death was seen in the high CABG SYNTAX Score group (≥22) compared to the low CABG SYNTAX Score group (<22) (14.5% vs. 9.1%, log rank p-value=0.012) (Figure 1). Similarly, significantly greater five-year all-cause death/cerebrovascular accident (CVA)/myocardial infarction (MI) (log rank p-value=0.025) and MACCE (major adverse cardiac and cerebrovascular events) (log rank p-value=0.050) were reported.

Figure 1. Outcomes (Kaplan-Meier curves) separated by the median of the CABG SYNTAX Score into low (0-21) (n=58) and high (≥22) (n=55) score groups. At 5 years, significantly greater all-cause mortality (left image), significantly greater all-cause death/CVA/MI (middle image) and MACCE (right image) were evident in the high CABG SYNTAX Score group compared to the low CABG SYNTAX Score group. Note the peak in MACCE at approximately 18 months secondary to patients undergoing scheduled coronary angiography, the findings of which triggered repeat revascularisation. Log rank p-values are shown.

Incomplete revascularisation (ICR) has recently been hypothesised and shown to be a surrogate marker of a greater burden and complexity of coronary disease, other vascular disease, and clinical comorbidity, in both CABG and PCI (percutaneous coronary intervention) treated patients4,5. Specifically, in the all-comers CABG and PCI arms of the SYNTAX trial, adverse long-term (four-year) clinical outcomes –including mortality, all-cause revascularisation, and MACCE– were shown to occur more frequently in patients who were incompletely revascularised.

The CABG SYNTAX Score and its PCI equivalent, the residual SYNTAX Score6, both provide objective measures of the complexity of the residual disease and level of revascularisation. These scores may aid in determining a level of “reasonable revascularisation” after undergoing surgical or percutaneous-based revascularisation7, and may have a long-term prognostic role in identifying high-risk patients undergoing CABG or PCI. Validation studies are awaited.

Acknowledgements

The authors would like to thank all the study centres and participants.

Funding

The SYNTAX trial was funded by Boston Scientific.

Conflict of interest statement

K. Dawkins is a full-time employee of, and holds stock in, Boston Scientific. M. Mack has served on the speakers bureau of Boston Scientific, Cordis and Medtronic. T. Feldman has served on the speakers bureau of Boston Scientific; has received grant support from Abbott, Atritech, Boston Scientific Corporation, Edwards, and Evalve; and has worked as a consultant for Abbott, Coherex, Intervalve, Square One, and WL Gore. M-A. Morel’s institution has received a research grant from Boston Scientific. M-A. Morel, H.M. Garcia-Garcia and G.A. van Es are employees of Cardialysis. The other authors have no conflicts of interest to declare.


References

Volume 9 Number 8
Dec 27, 2013
Volume 9 Number 8
View full issue


Key metrics

On the same subject

Editorial

10.4244/EIJ-E-23-00052 Mar 18, 2024
Comparative preclinical assessment of drug-coated balloons: a blessing and a curse for clinical translation
Joner M and Wild L
free

Debate

10.4244/EIJ-E-24-00005 Mar 18, 2024
Ischaemic and viability testing for guiding PCI are overrated: pros and cons
McEntegart M et al
free

Original Research

10.4244/EIJ-D-23-00725 Mar 18, 2024
A systematic algorithm for large-bore arterial access closure after TAVI: the TAVI-MultiCLOSE study
Rosseel L et al

Original Research

10.4244/EIJ-D-23-00783 Mar 18, 2024
Redo-TAVI with the ACURATE neo2 and Prime XL for balloon-expandable transcatheter heart valve failure
Meier D et al
Trending articles
281.88

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved